Anti-BTLA Agonist Therapy in Subjects With Primary Sjogren's Syndrome
NCT05781451
·
clinicaltrials.gov ↗
PHASE2
Phase
WITHDRAWN
Status
OTHER
Sponsor class
Stopped
Drug unavailable
Conditions
Primary Sjogren's Syndrome
Interventions
DRUG:
LY3361237
Sponsor
Stanford University